Syndax Pharmaceuticals, Inc. (SNDX): Price and Financial Metrics
Syndax Pharmaceuticals, Inc. (SNDX)
Today's Latest Price: $9.41 USD
1.34 (-12.47%)
Updated Feb 28 12:00am
Add SNDX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SNDX Stock Summary
- Syndax Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 8.87% of US listed stocks.
- With a price/sales ratio of 155.22, Syndax Pharmaceuticals Inc has a higher such ratio than 98.28% of stocks in our set.
- Revenue growth over the past 12 months for Syndax Pharmaceuticals Inc comes in at -34.94%, a number that bests just 5.47% of the US stocks we're tracking.
- Stocks that are quantitatively similar to SNDX, based on their financial statements, market capitalization, and price volatility, are OTIC, ARDX, RCUS, BCRX, and ATHX.
- Visit SNDX's SEC page to see the company's official filings. To visit the company's web site, go to www.syndax.com.
SNDX Daily Price Range
SNDX 52-Week Price Range
SNDX Stock Price Chart More Charts
SNDX Price/Volume Stats
| Current price | $9.41 | 52-week high | $11.33 |
| Prev. close | $10.75 | 52-week low | $4.52 |
| Day low | $9.11 | Volume | 395,600 |
| Day high | $10.70 | Avg. volume | 235,342 |
| 50-day MA | $9.01 | Dividend yield | N/A |
| 200-day MA | $8.35 | Market Cap | 255.39M |
Syndax Pharmaceuticals, Inc. (SNDX) Company Bio
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company was founded in 2005 and is based in Waltham, Massachusetts.
Top Stories View All
How Low Will Stocks Go?
Best & Worst Performing Stock Industries for February 28, 2020
Best & Worst Performing Small Cap Stocks for February 28, 2020
Best & Worst Performing Mid Cap Stocks for February 28, 2020
Best & Worst Performing Large Cap Stocks for February 28, 2020
View All Top Stories
Loading social stream, please wait...